IgA Nephropathy Market Set for Exceptional Growth by 2034 - DelveInsight | Key Players: Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others

IgA Nephropathy, a leading cause of kidney disease worldwide, continues to challenge both patients and healthcare systems with its complex progression and limited treatment options. The IgA nephropathy market is experiencing a significant transformation, driven by an increasing incidence, advancements in molecular research, and the advent of innovative therapies. With breakthroughs in immunotherapy, gene editing, and novel drug pipelines, the market is witnessing a shift toward more targeted and effective treatments.

DelveInsight's comprehensive report, IgA Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2034, provides an in-depth analysis of the current and future IgA nephropathy market landscape. It offers insights into the epidemiological segmentation, treatment dynamics, and emerging therapies across major markets, including the US, EU, and Japan. As the IgA nephropathy space continues to advance with promising pipeline innovations, the market is poised for remarkable growth and expansion through 2034.

Request a sample and uncover the latest breakthroughs shaping the IgA nephropathy market landscape and future outlook @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the IgA Nephropathy Market Report:
• IgA nephropathy (IgAN), also referred to as Berger's disease, is the most prevalent primary glomerular disease globally.
• According to DelveInsight's analysis, the IgAN market across the 7MM was valued at approximately USD 730 million in 2024. This market is expected to expand significantly during the forecast period from 2025 to 2034, growing at a CAGR of 30.5%.
• IgA nephropathy is more frequently observed in men, typically in their teens to late 30s, but it can develop at any age.
• DelveInsight estimates around 415K prevalent cases of IgAN across the 7MM in 2024. These diagnosed cases are expected to rise at a CAGR of 0.6% by 2034.
• In 2024, the US represented around 133K diagnosed prevalent cases of IgAN, with numbers projected to increase by 2034.
• In April 2025, Vera Therapeutics completed full enrollment in the pivotal ORIGIN Phase III trial evaluating atacicept for IgAN patients.
• In April 2025, Novartis received accelerated approval from the US FDA for VANRAFIA, the first selective ETAR antagonist to reduce proteinuria in primary IgAN patients at risk of rapid disease progression, based on early efficacy data.
• In September 2024, Travere Therapeutics received full FDA approval for FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN, supported by positive long-term data from the PROTECT Study.
• Currently, only a few treatments have been approved for IgAN, including VANRAFIA (Atrasentan) and FABHALTA (Iptacopan) by Novartis, FILSPARI (Sparsentan) by Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others.
• Emerging therapies for IgA nephropathy include Zigakibart, Sefaxersen, ULTOMIRIS, Atacicept, Povetacicept, Sibeprenlimab, Felzartamab, ARO-C3, NM8074, ADX-097, WAL0921, TAK-079, and others.
• Key companies involved in the treatment of IgA nephropathy include Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.

To know in detail about the IgA nephropathy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

IgA Nephropathy Overview
IgA Nephropathy (IgAN), also known as Berger's disease, is the most prevalent primary glomerular disorder worldwide. It is characterized by the deposition of Immunoglobulin A (IgA) in the kidneys, leading to inflammation and progressive kidney damage. IgAN commonly presents in individuals between the ages of 20 and 30, with a higher prevalence in males. The condition often manifests with symptoms such as hematuria (blood in the urine), proteinuria (excessive protein in the urine), and hypertension. Over time, IgAN can progress to end-stage renal disease (ESRD) if not properly managed.

The pathophysiology of IgA nephropathy involves the abnormal production and deposition of IgA in the glomeruli, triggering an inflammatory response that leads to kidney injury. Factors such as genetic predisposition, infections, and environmental influences contribute to the development and progression of the disease.

The diagnosis of IgAN is confirmed through kidney biopsy, which reveals the characteristic IgA deposits in the glomeruli. While there is no definitive cure for IgAN, the management includes controlling blood pressure, reducing proteinuria, and, in some cases, immunosuppressive therapies. Emerging treatments, including gene therapies and novel drug candidates, are being explored to offer better outcomes for patients. The IgA nephropathy market is expected to experience significant growth due to the increasing prevalence, advancements in treatment options, and the ongoing development of therapies that aim to slow or halt disease progression.

Get a free sample for the IgA nephropathy market forecast, size & share analysis report: https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

IgA Nephropathy Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

IgA Nephropathy Epidemiology Segmentation:
The IgA nephropathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Cases of IgAN
• Gender-specific Diagnosed Prevalent Cases of IgAN
• Age-specific Diagnosed Prevalent Cases of IgAN

IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section examines the adoption rates of newly launched and upcoming IgA nephropathy drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section provides a comprehensive overview of the factors that influence the acceptance and success of IgA nephropathy treatments on the market.

In addition, the therapeutics assessment section highlights the IgA nephropathy drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a comparison of market share among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption.

The report further explores the pipeline for IgA Nephropathy, providing insights into therapeutic candidates at various stages of development. It identifies the key companies involved in developing targeted treatments for IgA Nephropathy. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for IgA Nephropathy.

Explore how emerging IgA nephropathy therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

IgA Nephropathy Market Outlook
The IgA Nephropathy market is rapidly evolving, driven by increasing disease prevalence and advancements in treatment options. IgA nephropathy (IgAN), a leading cause of kidney failure, has traditionally been managed with supportive care, blood pressure control, and immunosuppressive therapies. However, the market is experiencing significant growth with the advent of targeted therapies aimed at improving treatment outcomes.

The introduction of new therapies, including TARPEYO/KINPEYGO (budesonide), FILSPARI (sparsentan), and VANRAFIA (atrasentan), is shifting the landscape by offering more effective ways to manage proteinuria and slow disease progression. These treatments have gained approval in major markets such as the US, EU, and UK, with VANRAFIA recently receiving FDA approval in April 2025.

Key players like Novartis, Travere Therapeutics, and Vera Therapeutics are spearheading innovation in the space, with therapies targeting specific molecular pathways to reduce inflammation and prevent kidney damage. Additionally, the market is benefiting from an increasing focus on precision medicine, with therapies tailored to individual patient profiles based on disease severity.

Despite the promising growth and new therapies, unmet needs persist in terms of efficacy, safety, and personalized care. These factors, along with the rising awareness of IgA nephropathy, are expected to continue driving market expansion over the coming years. As the IgA nephropathy market progresses, further developments in gene therapy, novel immunotherapies, and improved diagnostic techniques will likely further fuel market growth, making it a dynamic and critical area of focus for pharmaceutical companies and healthcare professionals alike.

IgA Nephropathy Market Drivers
• The development of new therapies, such as TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan), has significantly improved treatment options for IgA nephropathy, driving market growth by offering more effective management of proteinuria and slowing disease progression.
• Rising awareness of IgA nephropathy among both healthcare providers and patients is leading to earlier diagnosis and treatment, contributing to a growing patient population and expanding the market.

IgA Nephropathy Market Barriers
• Despite new therapies, the high cost of drugs like FILSPARI and VANRAFIA can limit access to treatment, particularly in lower-income regions or for patients without comprehensive insurance coverage, potentially slowing market growth.
• While recent therapies show promise, the long-term safety and efficacy data for many treatments remain limited. This uncertainty could hinder patient and provider adoption and restrict the widespread use of newer therapies.

Scope of the IgA Nephropathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key IgA Nephropathy Companies: Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.
• Key IgA Nephropathy Therapies: Zigakibart, Sefaxersen, ULTOMIRIS, Atacicept, Povetacicept, Sibeprenlimab, Felzartamab, ARO-C3, NM8074, ADX-097, WAL0921, TAK-079, and others.
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy currently marketed, and IgA Nephropathy emerging therapies.
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• IgA Nephropathy Unmet Needs, KOL's views, Analyst's views, IgA Nephropathy Market Access and Reimbursement.

To learn more about IgA nephropathy companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. IgA Nephropathy Market Report Introduction
2. Executive Summary for IgA Nephropathy
3. SWOT analysis of IgA Nephropathy
4. IgA Nephropathy Patient Share (%) Overview at a Glance
5. IgA Nephropathy Market Overview at a Glance
6. IgA Nephropathy Disease Background and Overview
7. IgA Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of IgA Nephropathy
9. IgA Nephropathy Current Treatment and Medical Practices
10. IgA Nephropathy Unmet Needs
11. IgA Nephropathy Emerging Therapies
12. IgA Nephropathy Market Outlook
13. Country-Wise IgA Nephropathy Market Analysis (2020-2034)
14. IgA Nephropathy Market Access and Reimbursement of Therapies
15. IgA Nephropathy Market Drivers
16. IgA Nephropathy Market Barriers
17. IgA Nephropathy Appendix
18. IgA Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.